RBR-4jbw4s
Completed
N/A
se of Botulinum Toxin Type A for Treatment of Idiopathic Rhinitis
Faculdade de Medicina da Universidade de São Paulo0 sitesJuly 23, 2020
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- idiopathic rhinitis
- Sponsor
- Faculdade de Medicina da Universidade de São Paulo
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Criteria for inclusion in the study: Patients older than 18 years who signed the informed consent form and understood the explanation of the study, carried out by the researcher himself. Patients of both sexes, without distinction of race. Patients diagnosed for idiopathic rhinitis for at least one year, ie patients in whom the other etiologies of rhinitis (allergic rhinitis, non\-allergic, drug, hormonal, drug and occupational eosinophilic rhinitis) were excluded from the clinical history , physical examination, nasal cytology examination with eosinophils below 2%, and immediate hypersensitivity skin test for negative inhalants.
Exclusion Criteria
- •Exclusion criteria in the study: Patients with other nasal anatomical abnormalities, such as nasosinusal polyposis or obstructive nasal septum deviation. Patients with acute or chronic rhinosinusitis. Patients with severe systemic diseases, glaucoma or prostatic hypertrophy that may be aggravated by anticholinergic therapy. Patients with immediate hypersensitivity skin test for positive inhalants, nasal cytological examination with eosinophilia greater than 2%.Patients who received rhinitis medications prior to the immediate inhalant hypersensitivity skin test. Patients pregnant or likely to be pregnant.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
N/A
Botulin Toxin injection for the treatment of Internal Anal Sphincter AchalasiaEUCTR2005-002335-27-ITISTITUTO GIANNINA GASLINI
Active, Not Recruiting
Phase 1
How affect the salivary gland treatment with Botulinum neurotoxin type A oral health in patients suffer for drooling?HypersalivationMedDRA version: 18.0Level: LLTClassification code 10020746Term: HypersalivationSystem Organ Class: 100000004856Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]EUCTR2015-000682-30-EETartu University Hospital90
Recruiting
Phase 4
Efficacy of botulinum toxin A for the management of melasma: A split-face, randomized control studyClinical diagnosis of melasma with symmetrical involvement of both malar areasMelasmaTCTR20240721002Division of Dermatology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand30
Not Yet Recruiting
N/A
Assessment of Botulinum Toxin Type A in the Treatment of Hand EczemaPACTR201704002194318Dermatology Department, Faculty of Medicine, University of Alexandria60
Completed
Phase 3
A study of onabotulinum toxin type A for the treatment of ultraviolet B-induced hyperpigmentation: a prospective, randomized, controlled trialVB-induced hyperpigmentationUVB, hyperpigmentation, onabotulinum toxinTCTR20211111002Division of Dermatology, Department of medicine, Faculty of Medicine, Ramathibodi hospital15